Begin main content

halobetasol propionate and tazarotene

Last Updated: January 7, 2019
Result type: Reports
Project Number: SR0600-000
Product Line: Common Drug Review

Generic Name: halobetasol propionate and tazarotene

Brand Name: TBC

Manufacturer: Bausch Health, Canada Inc.

Indications: Psoriasis, moderate to severe plaque

Manufacturer Requested Reimbursement Criteria1:

Topical treatment of moderate-to-severe plaque psoriasis in adult patients.

Submission Type: New

Project Status: Pending

Call For Patient Input: January 7, 2019

Patient Input Closed: February 26, 2019

Anticipated Date: February 4, 2019

Biosimilar: No

Fee Schedule: Pending

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Submit Feedback